These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38538206)

  • 61. Inclisiran: First Approval.
    Lamb YN
    Drugs; 2021 Feb; 81(3):389-395. PubMed ID: 33620677
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PCSK9 inhibition for autosomal recessive hypercholesterolemia.
    Chemello K; Martín C; Lambert G
    Atherosclerosis; 2019 May; 284():209-211. PubMed ID: 30862376
    [No Abstract]   [Full Text] [Related]  

  • 64. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 65. RNA Silencing in the Management of Dyslipidemias.
    Henney NC; Banach M; Penson PE
    Curr Atheroscler Rep; 2021 Sep; 23(11):69. PubMed ID: 34468873
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reducing cholesterol levels to decrease cardiovascular events: the role of new proprotein convertase subtilisin/kexin type 9 inhibitors.
    Alberto Z
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e184-e186. PubMed ID: 27841824
    [No Abstract]   [Full Text] [Related]  

  • 68. Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol.
    Seidah NG
    Nat Struct Mol Biol; 2017 Oct; 24(10):785-786. PubMed ID: 28981076
    [No Abstract]   [Full Text] [Related]  

  • 69. Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia.
    Baass A; Hegele RA
    Can J Cardiol; 2018 Aug; 34(8):959-961. PubMed ID: 30056849
    [No Abstract]   [Full Text] [Related]  

  • 70. Inclisiran: A Game Changer in a Changing Game?
    Nambi V; Agha A
    J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736
    [No Abstract]   [Full Text] [Related]  

  • 71. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.
    Rached F; Santos RD
    Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lipid Lowering Drugs: Present Status and Future Developments.
    Ruscica M; Ferri N; Santos RD; Sirtori CR; Corsini A
    Curr Atheroscler Rep; 2021 Mar; 23(5):17. PubMed ID: 33694108
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Estimation of the major cardiovascular events prevention with Inclisiran.
    Cordero A; Santos-Gallego CG; Fácila L; Rodríguez-Mañero M; Bertomeu-González V; Castellano JM; Seijas-Amigo J; Núñez J; Zuazola P; González-Juanatey JR; Badimon JJ
    Atherosclerosis; 2020 Nov; 313():76-80. PubMed ID: 33032236
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
    Leong D; Wu PE
    CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
    [No Abstract]   [Full Text] [Related]  

  • 75. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents.
    Stoll F; Eidam A; Michael L; Bauer JM; Haefeli WE
    Drugs Aging; 2022 Apr; 39(4):251-256. PubMed ID: 35278206
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 80. What is the role of PCSK9 inhibitors in treating hypercholesterolemia?
    Volpe M
    JAAPA; 2018 Jun; 31(6):14-15. PubMed ID: 29846311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.